HC Wainwright Analysts Give uniQure (QURE) a $28.00 Price Target
uniQure (NASDAQ:QURE) has been assigned a $28.00 price objective by equities researchers at HC Wainwright in a research report issued on Thursday. The firm currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price would indicate a potential upside of 64.51% from the stock’s current price.
QURE has been the topic of several other reports. Zacks Investment Research cut shares of uniQure from a “buy” rating to a “hold” rating in a research report on Friday, November 10th. Evercore ISI initiated coverage on shares of uniQure in a research report on Tuesday, November 7th. They set an “outperform” rating and a $22.00 target price on the stock. ValuEngine cut shares of uniQure from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Oppenheimer restated a “hold” rating on shares of uniQure in a research report on Friday, November 24th. Finally, Leerink Swann upped their target price on shares of uniQure from $17.00 to $19.00 and gave the company an “outperform” rating in a research report on Friday, October 20th. One analyst has rated the stock with a sell rating, three have issued a hold rating and five have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $19.29.
uniQure (NASDAQ:QURE) traded up $2.02 on Thursday, hitting $17.02. 1,642,200 shares of the company’s stock traded hands, compared to its average volume of 310,974. uniQure has a twelve month low of $4.72 and a twelve month high of $21.35. The company has a quick ratio of 3.64, a current ratio of 3.64 and a debt-to-equity ratio of 0.73.
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.
Receive News & Ratings for uniQure N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure N.V. and related companies with MarketBeat.com's FREE daily email newsletter.